(MENAFN- GlobeNewsWire - Nasdaq) Key market opportunities for abemaciclib include growing demand for targeted therapies in oncology, advancements in combination therapies with immuno-oncology, and integration of personalized medicine. Emerging markets in Asia-Pacific, expanded cancer treatment access, and innovations in therapy delivery methods further bolster growth.

Dublin, Dec. 02, 2025 (GLOBE NEWSWIRE) -- The "Abemaciclib Market Report 2025" report has been added to ResearchAndMarkets's offering.
The abemaciclib market size has grown rapidly in recent years. It will grow from $1.42 billion in 2024 to $1.6 billion in 2025 at a compound annual growth rate (CAGR) of 12.5%. The growth during the historic period was driven by increasing clinical trial success rates for CDK4 and CDK6 inhibitors, growing adoption of targeted therapies in oncology, rising use of adjuvant therapy in early breast cancer, expanded availability of companion diagnostics, and increased patient advocacy and awareness campaigns.

The abemaciclib market size is expected to see rapid growth in the next few years. It will grow to $2.54 billion in 2029 at a compound annual growth rate (CAGR) of 12.2%. The growth during the forecast period is fueled by rising approvals of combination therapies with immuno-oncology, a growing pipeline of novel formulations and next-generation CDK inhibitors, expanded access to cancer treatment through government programs, increased biomarker-based patient selection, and longer therapy duration following positive overall survival outcomes. The primary trends in the forecast period include advancements in targeted therapy applications, integration of personalized medicine, expansion into emerging markets, innovation in formulation and delivery methods, and progress in clinical trial applications.
The rising incidence of breast cancer is expected to drive the growth of the abemaciclib market in the coming years. Breast cancer is a malignant tumor that originates in the breast tissue, mainly affecting the ducts or lobules, and has the potential to spread to other parts of the body if not treated. The increasing incidence of breast cancer is primarily due to enhanced detection and screening techniques, which allow for more diagnoses of cases that might have otherwise gone undetected.

Abemaciclib helps manage breast cancer by inhibiting specific enzymes that promote tumor cell growth, thereby slowing disease progression and improving patient outcomes. For example, in February 2025, the International Agency for Research on Cancer (IARC), a France-based intergovernmental agency, reported that in 2022, approximately 2.3 million women were diagnosed with breast cancer globally, resulting in 670,000 deaths. Projections estimate 3.2 million cases and 1.1 million deaths annually by 2050. As a result, the increasing prevalence of breast cancer is driving the expansion of the abemaciclib market.
Companies operating in the abemaciclib market are focusing on innovations such as combination therapy with endocrine treatment to enhance treatment efficacy, reduce recurrence in high-risk early breast cancer patients, and expand therapeutic options across different stages of HR+, HER2- breast cancer. Combination therapy with endocrine treatment involves using abemaciclib alongside hormone-blocking therapy to more effectively slow or halt the growth of HR+ breast cancer cells.

When used in combination with endocrine therapy, Ramiven improves treatment efficacy and reduces the likelihood of cancer returning. This launch significantly expands access to advanced, targeted therapies for high-risk breast cancer patients in India. The combination of abemaciclib with endocrine therapy aims to enhance patient outcomes and provide a more effective treatment strategy.
In February 2022, Veru Inc., a US-based biopharmaceutical company, collaborated with Eli Lilly and Company to advance the development and commercialization of targeted therapies focused on women's health and oncology. The partnership aims to assess the safety and effectiveness of combining Veru's enobosarm with Eli Lilly's Verzenio (abemaciclib) for second-line treatment of AR+ER+HER2 metastatic breast cancer. Eli Lilly and Company, which develops and provides abemaciclib, is working on providing more comprehensive treatment options for advanced and early breast cancer.
Major player in the in the abemaciclib market is Eli Lilly and Company.
North America was the largest region in the abemaciclib market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in abemaciclib report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the abemaciclib market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Reasons to Purchase:

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Key Attributes:

Report Attribute	Details
No. of Pages	250
Forecast Period	2025 - 2029
Estimated Market Value (USD) in 2025	$1.6 Billion
Forecasted Market Value (USD) by 2029	$2.54 Billion
Compound Annual Growth Rate	12.2%
Regions Covered	Global

Key Topics Covered:
1. Executive Summary
2. Abemaciclib Market Characteristics
3. Abemaciclib Market Trends and Strategies
4. Abemaciclib Market - Macro Economic Scenario Including the Impact of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, and Covid and Recovery on the Market
4.1. Supply Chain Impact from Tariff War & Trade Protectionism
5. Global Abemaciclib Growth Analysis and Strategic Analysis Framework
5.1. Global Abemaciclib PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis of End Use Industries
5.3. Global Abemaciclib Market Growth Rate Analysis
5.4. Global Abemaciclib Historic Market Size and Growth, 2019-2024, Value ($ Billion)
5.5. Global Abemaciclib Forecast Market Size and Growth, 2024-2029, 2034F, Value ($ Billion)
5.6. Global Abemaciclib Total Addressable Market (TAM)
6. Abemaciclib Market Segmentation
6.1. Global Abemaciclib Market, Segmentation by Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

• Tablets
• Capsules
• Other Product Types

6.2. Global Abemaciclib Market, Segmentation by Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

• Advanced or Metastatic Breast Cancer
• Early Breast Cancer
• Other Indications

6.3. Global Abemaciclib Market, Segmentation by Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

• Online
• Offline

6.4. Global Abemaciclib Market, Segmentation by End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

• Hospitals
• Cancer Treatment Centers
• Other End-Users

6.5. Global Abemaciclib Market, Sub-Segmentation of Tablets, by Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

• Standard Tablets
• Extended-Release Tablets

6.6. Global Abemaciclib Market, Sub-Segmentation of Capsules, by Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

• Hard Gelatin Capsules
• Soft Gelatin Capsules

6.7. Global Abemaciclib Market, Sub-Segmentation of Other Product Types, by Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

• Oral Suspensions
• Injectable Forms
• Topical Forms

7. Abemaciclib Market Regional and Country Analysis
7.1. Global Abemaciclib Market, Split by Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Abemaciclib Market, Split by Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

For more information about this report visit

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Attachment

• Abemaciclib Market

CONTACT: CONTACT: Laura Wood,Senior Press Manager... For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

MENAFN02122025004107003653ID1110423779